Phaseline

Companies › Xizang Haisco Pharmaceutical

Xizang Haisco Pharmaceutical: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 1 Phase 1, 1 Phase 2; Oncology, Immunology; next expected readout Feb 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
HSK44459–Phase 2Atopic Dermatitis (AD)–
HSK39775–Phase 1Advanced Solid TumorsFeb 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06996912HSK44459Phase 2Atopic Dermatitis (AD)ImmunologyJan 2026
NCT06314373HSK39775Phase 1Advanced Solid TumorsOncologyFeb 2028

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Tavotek Biotherapeutics Telios Pharma Molecure Antengene Biologics Ganzhou Hemay Pharmaceutical

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.